Results 161 to 170 of about 16,901 (224)

Seroprevalence and risk factors for Lassa virus infection in South-West and North-Central Nigeria: a community-based cross-sectional study. [PDF]

BMC Infect Dis
Tiamiyu AB, Adegbite OA, Freides O, Frndak S, Mohammed SS, Broach E, Lombardi K, Anyebe V, Akiga R, Okeke NC, Feyisayo JE, Ugwuezumba O, Akinde C, Osuji A, Agu N, Analogbei T, Ekweremadu C, Bartolanzo D, Prins P, Fan Y, Emekaili D, Abah F, Chiwetelu V, Dike P, Isaiah E, Ayogu M, Ogunkelu E, Agbaim UC, Bukunmi A, Adamu Y, Mebrahtu T, Zuppe A, Johnston M, Modjarrad K, Meri H, Parker Z, Akinwale E, McCauley MD, Schluck G, King DB, Eller LA, Okeji N, Ayemoba OR, Collins ND, Iroezindu MO, Hakre S, EID023 Lassa study team.   +46 more
europepmc   +1 more source

Microbiology: a dangerous profession? [PDF]

, 2010
Mercè Piqueras
core   +2 more sources

Lassa virus persistence with high viral titers following experimental infection in its natural reservoir host, Mastomys natalensis. [PDF]

Nat Commun
Hoffmann C, Krasemann S, Wurr S, Hartmann K, Adam E, Bockholt S, Müller J, Günther S, Oestereich L.   +8 more
europepmc   +1 more source

Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses. [PDF]

Cell Rep
Brouwer PJM, Perrett HR, Beaumont T, Nijhuis H, Kruijer S, Burger JA, Bontjer I, Lee WH, Ferguson JA, Schauflinger M, Müller-Kräuter H, Sanders RW, Strecker T, van Gils MJ, Ward AB.   +14 more
europepmc   +1 more source

A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison. [PDF]

F1000Res
Antonelli R, Forconi V, Molesti E, Semplici C, Piu P, Altamura M, Dapporto F, Temperton N, Montomoli E, Manenti A.   +9 more
europepmc   +1 more source

Lassa virus Z protein hijacks the autophagy machinery for efficient transportation by interrupting CCT2-mediated cytoskeleton network formation. [PDF]

Autophagy
Yuan Y, Fang A, Zhang M, Zhou M, Fu ZF, Zhao L.   +5 more
europepmc   +1 more source

Correction: Murphy, H.; Ly, H. Understanding Immune Responses to Lassa Virus Infection and to Its Candidate Vaccines. Vaccines 2022, 10, 1668. [PDF]

Vaccines (Basel)
Murphy H, Ly H.
europepmc   +1 more source

MHC-I alleles mediate clearance and antibody response to the zoonotic Lassa virus in Mastomys rodent reservoirs. [PDF]

PLoS Negl Trop Dis
Olayemi A, Schmid DW, Fleischer R, Wilhelm K, Heni AC, Mueller-Klein N, Haikukutu L, Fichet-Calvet E, Günther S, Sommer S.   +9 more
europepmc   +1 more source

Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus. [PDF]

Cell Rep Med
Cross RW, Fenton KA, Woolsey C, Prasad AN, Borisevich V, Agans KN, Deer DJ, Dobias NS, Fears AC, Heinrich ML, Geisbert JB, Garry RF, Branco LM, Geisbert TW.   +13 more
europepmc   +1 more source